【2026Year1Month9Day, Hong Kong/【Suzhou】Today, Suzhou Ribo Life Science Co., Ltd. (hereinafter referred to as“Ribo Life Science”`, Stock Code:`06938.HK) officially listed on the Main Board of the Hong Kong Stock Exchange.As a pioneer and leading company in the research and development of small nucleic acid drugs in Asia, Ribo Life Science's global offering totalsIssued 31,610,400 shares at an issue price of HKD 57.97 per share, raising a total of over 1.8 billion Hong Kong dollars.Attracted strong support from more than ten top-tier cornerstone investors both in China and internationally, including Huaxia Fund, Taikang Life Insurance, Dacheng Fund, and Pickstone Partners.

As the listing bell rang, Ribo Life Science not only completed the transition fromBiotechThe brilliant transformation into an international pharmaceutical enterprise also marks the strength of China's original innovative drugs.siRNA(Small interferingRNA) This trillion-dollar track has officially started with international small nucleic acid giantsAlnylam、ArrowheadA New Journey of Competing on the Same Stage.

Figure 1. Ribo Life Science Listed on the Main Board of the Hong Kong Stock Exchange

The successful listing of Ribo Life Science is inseparable from the long-term efforts of its founder, Dr. Zicai Liang, and his team in the small nucleic acid field.19Years of continuous深耕. As an internationally renowned nucleic acid technology expert, Dr. Liang early on foresaw with great presciencesiRNAThe Disruptive Potential of Technology in Reshaping the Treatment Model for Chronic Diseases.

“Small nucleic acid drugs act directly upstream of protein synthesis.‘Assembly Line’，Make Traditional‘Undruggable’Becoming a target is possible.”Dr. Liang Zicai once explained its core value in this way.2007Since its establishment in [Year], Ribo Life Science has always adhered to“Rooted in China, Global Perspective”, the international clinical trial base established in Sweden (CTU) enabling it to independently conduct2The ability in Phase clinical trials. This deep integration of scientific spirit and international operation constitutes the irreplaceable strategic depth of Ribo Life Science, forming its unique and strong competitiveness.

Ribo Life Science currently has a highly differentiated and well-structured R&D pipeline, with multiple candidate drugs already ranking among the world's top tier in terms of clinical progress and efficacy indicators:

• RBD4059(TargetedFXI): Anticoagulation Field“Globally Unique”As the world's first and fastest progressing targetedFXIThesiRNADrug,RBD4059Directly targeting thrombotic diseases.2025Year11In the month, Bayer announced its small moleculeFXIInhibitorAsundexianThe success of the Phase III clinical trial further validatedFXIThe Great Potential of Targets in the Field of Cardiovascular and Cerebrovascular Diseases.

Global Comparison:Unlike the drawback of traditional anticoagulants that easily lead to bleeding,RBD4059Achieved“Antithrombotic without causing bleeding”The precise treatment effect. In the global race to develop small nucleic acid drugs targeting similar mechanisms,Ribo Life Science is currently inLeading Position。

• RBD5044(TargetedAPOC3): Targeting the Billion-Dollar Market for Hypertriglyceridemia

RBD5044Is the second globally developed targetedAPOC3ThesiRNADrug Targets Billion-Dollar Cardiovascular Market。

Competitive Comparison:Compared with the marketedASODrug,RBD5044With stronger lipid-lowering efficacy, superior safety, and significantly reduced dosing frequency, it is highly commercially competitive.

• RBD1016(TargetedHBV-X）：Committed to achieving "functional cure" for hepatitis B. This drug is intended to be a core component of future combination therapies for hepatitis B, targeting the global market.2.5Hundreds of millions of patients have achieved clinical cure, and its clinical potential in virus knockdown efficiency is comparable to or even better than international counterparts. In addition,RBD1016The indication for Hepatitis D has been granted EU Orphan Drug Designation.

Figure 2.Ribo Life ScienceR&D Pipeline, Source: Company Prospectus

Ribo Life Science Successfully Builds a Platform with Independent Intellectual Property RightsRiboGalSTAR™ Delivery Platform`, which not only ensures the company's R&D independence but also demonstrates extremely high commercial value.`2023Year12In the month, Ribo Life Science and Boehringer Ingelheim reached an agreement with a total amount exceeding20The strategic cooperation in the amount of hundreds of millions of US dollars confirms the international recognition of its technological platform.

In addition, the company is actively expanding its extrahepatic delivery technology,RiboPepSTAR™The platform can specifically target tissues such as the kidneys, central nervous system, fat, and muscles, laying the foundation for the application of small nucleic acid drugs in a wider range of fields.

This HKEX listing will strongly accelerate the commercialization process and global development of Ribo Life Science. The proceeds will mainly be used for core products.RBD4059AndRBD5044Clinical development, R&D platform upgrades, and global layout.

With the support of the capital market, Ribo Life Science is“Leading in China”Towards“Global Leader”. In this place hailed as“The Third Pharmaceutical Revolution”In the tide, Ribo Life Science is making its mark on the global biopharmaceutical高地 with its solid academic accumulation, advanced delivery technology, and highly internationally competitive pipeline, representing Chinese biopharmaceutical enterprises.